PKC-IN-4

• Description:

  PKC-IN-4 (compound 7l) is a potent and orally active aPKC inhibitor with an IC50 of 0.52 μM. PKC-IN-4 inhibits TNF-α induced NF-κB activity in vitro. PKC-IN-4 blocks VEGF- and TNFα-induced permeability across the retinal vasculature[1].

• UNSPSC:

  12352005

• Target:

  PKC

• Type:

  Reference compound

• Related Pathways:

  Epigenetics; TGF-beta/Smad

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/pkc-in-4.html

• Solubility:

  10 mM in DMSO

• Smiles:

  NCC1CCN (CC1) C2=NC (C3=CC=NC=C3) =NC4=C2C5=C (S4) CCCC5

• Molecular Formula:

  C21H25N5S

• Molecular Weight:

  379.52

• References & Citations:

  [1]Liu X, et al. Synthesis and structure-activity relationships of thieno[2,3-d]pyrimidines as atypical protein kinase C inhibitors to control retinal vascular permeability and cytokine-induced edema. Bioorg Med Chem. 2020 Jun 1;28 (11) :115480.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  PKC

• CAS Number:

  2636771-29-2